Teva Pharmaceutical Industries Ltd TEVA.N, TEVA.K is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2025
The Tel Aviv-yafo Israel-based company is expected to report a 4.4% increase in revenue to $3.988 billion from $3.82 billion a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Teva Pharmaceutical Industries Ltd is for earnings of 46 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Teva Pharmaceutical Industries Ltd is $21.50, above its last closing price of $16.19.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | 0.73 | 0.70 | 0.71 | Beat | 1.2 |
Sep. 30 2024 | 0.67 | 0.66 | 0.69 | Beat | 4.5 |
Jun. 30 2024 | 0.58 | 0.55 | 0.61 | Beat | 10.7 |
Mar. 31 2024 | 0.51 | 0.51 | 0.48 | Missed | -6.7 |
Dec. 31 2023 | 0.77 | 0.77 | 1.00 | Beat | 30.3 |
Sep. 30 2023 | 0.61 | 0.61 | 0.60 | Missed | -1.4 |
Jun. 30 2023 | 0.52 | 0.53 | 0.56 | Beat | 6.6 |
Mar. 31 2023 | 0.56 | 0.56 | 0.40 | Missed | -28.1 |
This summary was machine generated May 5 at 12:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)